CN1674888A - 用于治疗癌症的化合物、其组合物和它们的使用方法 - Google Patents

用于治疗癌症的化合物、其组合物和它们的使用方法 Download PDF

Info

Publication number
CN1674888A
CN1674888A CNA038193191A CN03819319A CN1674888A CN 1674888 A CN1674888 A CN 1674888A CN A038193191 A CNA038193191 A CN A038193191A CN 03819319 A CN03819319 A CN 03819319A CN 1674888 A CN1674888 A CN 1674888A
Authority
CN
China
Prior art keywords
alkyl
replacement
unbranched
branch
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038193191A
Other languages
English (en)
Chinese (zh)
Inventor
J·麦肯纳
F·默库里奥
V·普兰特文
W·谢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signal Pharmaceuticals LLC
Original Assignee
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharmaceuticals LLC filed Critical Signal Pharmaceuticals LLC
Publication of CN1674888A publication Critical patent/CN1674888A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
CNA038193191A 2002-06-17 2003-06-17 用于治疗癌症的化合物、其组合物和它们的使用方法 Pending CN1674888A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38946102P 2002-06-17 2002-06-17
US60/389,461 2002-06-17
US10/463,009 2003-06-16
US10/463,009 US7037936B2 (en) 2002-06-17 2003-06-16 Compounds useful for the treatment of cancer, compositions thereof and methods therewith

Publications (1)

Publication Number Publication Date
CN1674888A true CN1674888A (zh) 2005-09-28

Family

ID=29740147

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038193191A Pending CN1674888A (zh) 2002-06-17 2003-06-17 用于治疗癌症的化合物、其组合物和它们的使用方法

Country Status (10)

Country Link
US (2) US7037936B2 (enExample)
EP (1) EP1551388A4 (enExample)
JP (1) JP2006515560A (enExample)
CN (1) CN1674888A (enExample)
AU (1) AU2003243587B2 (enExample)
CA (1) CA2488891A1 (enExample)
IL (1) IL165839A0 (enExample)
MX (1) MXPA04012675A (enExample)
NZ (1) NZ537653A (enExample)
WO (1) WO2003105774A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985405A (zh) * 2010-07-02 2013-03-20 Aska制药株式会社 杂环化合物及p27Kip1分解抑制剂

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
US8175808B2 (en) * 2005-04-01 2012-05-08 Sloan Kettering Institute For Cancer Research Method for determining disease treatment duration
CA2632968A1 (en) 2005-12-02 2007-06-07 Isis Pharmaceuticals, Inc. Antibacterial 4,5-substituted aminoglycoside analogs having multiple substituents
WO2010030704A2 (en) 2008-09-10 2010-03-18 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2010030690A1 (en) 2008-09-10 2010-03-18 Isis Pharmaceuticals, Inc. Antibacterial 4,6-substituted 6', 6" and 1 modified aminoglycoside analogs
WO2010042850A1 (en) 2008-10-09 2010-04-15 Achaogen, Inc. Antibacterial aminoglycoside analogs
WO2010042851A1 (en) 2008-10-09 2010-04-15 Achaogen, Inc. Antibacterial aminoglycoside analogs
EP2486044A2 (en) 2009-10-09 2012-08-15 Achaogen, Inc. Antibacterial aminoglycoside analogs
TW201304784A (zh) 2010-11-17 2013-02-01 Achaogen Inc 抗菌性胺基糖苷類似物
WO2012075232A1 (en) * 2010-12-04 2012-06-07 Trevena, Inc. Opioid receptor ligands and methods of using and making the same
JP2024523237A (ja) 2021-06-18 2024-06-28 ホンジーン バイオテック コーポレイション 官能化されたｎ－アセチルガラクトサミンヌクレオシド
WO2023034719A1 (en) 2021-08-30 2023-03-09 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
EP4448540A1 (en) 2021-12-15 2024-10-23 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328249A (en) * 1965-06-21 1967-06-27 Sterling Drug Inc Process for counteracting depressive states
US3485873A (en) * 1966-12-21 1969-12-23 Sterling Drug Inc N-benzyl-n-methyl-omega-phenyl-omega-cycloalkyl-lower-alkylamines
GB9201755D0 (en) 1992-01-28 1992-03-11 British Bio Technology Compounds
CA2341064A1 (en) 1998-08-28 2000-03-09 New York University Novel ubiquitin ligases as therapeutic targets
DE69943222D1 (de) 1998-12-10 2011-04-07 Signal Pharm Llc Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
US20010044445A1 (en) * 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
WO2002055665A2 (en) 2001-01-05 2002-07-18 Univ New York Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
MXPA04011930A (es) * 2002-05-31 2005-03-31 Yamanouchi Pharma Co Ltd Derivados de tetrahidropirano.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985405A (zh) * 2010-07-02 2013-03-20 Aska制药株式会社 杂环化合物及p27Kip1分解抑制剂
CN102985405B (zh) * 2010-07-02 2016-07-06 Aska制药株式会社 杂环化合物及p27Kip1分解抑制剂
CN105753858A (zh) * 2010-07-02 2016-07-13 Aska制药株式会社 杂环化合物及p27Kip1分解抑制剂
CN105753858B (zh) * 2010-07-02 2019-04-30 Aska制药株式会社 杂环化合物及p27Kip1分解抑制剂

Also Published As

Publication number Publication date
US20060142352A1 (en) 2006-06-29
US7037936B2 (en) 2006-05-02
JP2006515560A (ja) 2006-06-01
AU2003243587A1 (en) 2003-12-31
US20060030617A1 (en) 2006-02-09
IL165839A0 (en) 2006-01-15
EP1551388A2 (en) 2005-07-13
EP1551388A4 (en) 2009-07-15
CA2488891A1 (en) 2003-12-24
MXPA04012675A (es) 2005-08-15
WO2003105774A2 (en) 2003-12-24
AU2003243587B2 (en) 2008-02-28
NZ537653A (en) 2007-09-28
WO2003105774A3 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
CN1674888A (zh) 用于治疗癌症的化合物、其组合物和它们的使用方法
CN1077107C (zh) 杂环化合物、其制备和用途
CN1269813C (zh) 作为细胞增生抑制剂的咪唑－5－基－2－苯胺基－嘧啶
CN1159289C (zh) 作为ICE/ced-3族半胱氨酸蛋白酶抑制剂的C端修饰的草氨酰二肽
CN1149204C (zh) 1-杂环取代的二芳基胺
CN1049891C (zh) 双环胺类化合物及其制备方法和含该化合物的药物组合物
CN1542002A (zh) 金属蛋白酶抑制剂,含有它们的药物组合物和其药物用途,其制备方法和中间体
CN1568322A (zh) 作为蛋白jun激酶抑制剂的有亲油和可离子化部分的药学活性磺酰胺衍生物
CN1872850A (zh) N－苯基－2－嘧啶胺衍生物
CN1832939A (zh) 用于治疗癌症或病毒病的三杂环化合物、组合物和方法
CN1633419A (zh) Cdk抑制性嘧啶化合物、其制备方法以及作为药物的应用
CN1214011C (zh) 作为整联蛋白拮抗剂的间－氮杂环氨基苯甲酸化合物及其衍生物
CN1255162A (zh) 蛋白酶抑制剂
CN1355790A (zh) 采用二氢异吲哚衍生物抑制淀粉样蛋白聚集和使淀粉样蛋白沉积成像的方法
CN1237960A (zh) N(－芳基/杂芳基乙酰基)氨基酸酯、包括这些酯的药用组合物以及用这些化合物抑制β淀粉样肽释放和/或合成的方法
CN1675189A (zh) 苯并噻唑衍生物的新用途
CN1061407A (zh) 用作白细胞三烯拮抗物的不饱和羟烷基喹啉羧酸
CN1330648A (zh) 作为jnk蛋白质激酶抑制剂的4－芳基羟吲哚
CN1350528A (zh) 作为抗肿瘤剂的4,5,6,7－四氢吲唑衍生物
CN1279669A (zh) 芳族砜异羟肟酸金属蛋白酶抑制剂
CN1332737A (zh) 凝血酶抑制剂
CN1226826A (zh) 用无明显激素活性的甲状腺素类似物治疗恶性肿瘤的方法
CN1171116A (zh) 作为因子Xa抑制剂的N－取代甘氨酸衍生物
CN1443173A (zh) 作为TAFIa抑制剂的取代的咪唑
CN1764655A (zh) 芳族砜异羟肟酸酯及其作为蛋白酶抑制剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1083742

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20050928

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1083742

Country of ref document: HK